Lantheus Holdings, Inc. (LNTH)

NGM – Real Time Price. Currency in USD

96.23

+2.16 (2.30%)

At close: May 12, 2026, 4:00 PM EDT

95.99

-0.24 (-0.25%)

Pre-market: May 13, 2026, 9:07 AM EDT

08.05.2026

Lantheus Q1 Earnings Call Highlights

Lantheus NASDAQ: LNTH reported what management described as a strong start to 2026, citing solid performance from its three core commercial products—PYLARIFY, Neuraceq® and DEFINITY—and progress on multiple regulatory and pipeline milestones during the first quarter.

08.05.2026

These Analysts Raise Their Forecasts On Lantheus After Upbeat Q1 Results

Lantheus Holdings Inc (NASDAQ:LNTH) reported upbeat earnings for the first quarter on Thursday.

08.05.2026

Lantheus Holdings, Inc. (LNTH) Q1 2026 Earnings Call Transcript

07.05.2026

Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

BEDFORD, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its first quarter ended March 31, 2026.

29.04.2026

Brown Advisory Small Cap Growth Strategy Q1 2026 Portfolio Activity

Shares of Lantheus Holdings were added after the company received FDA approval of its key product TruVu. We used recent weakness as an opportunity to initiate a position in Talen Energy, an independent power producer whose portfolio includes the Susquehanna nuclear plant and other dispatchable generation assets. We exited Cactus as we lost confidence that its major growth lever, expansion into the Middle East, would play out in 2026 amid the escalating conflict in the region.

07.04.2026

Lantheus Holdings: Tensions From The PDUFA Extension

Lantheus Holdings faces a three-month FDA PDUFA extension for OCTEVY, delaying potential approval and launch to June 2026. OCTEVY's extension is procedural, tied to manufacturing review, not efficacy or safety, and is not expected to impact its clinical adoption pathway. While OCTEVY alone won't restore double-digit growth, it can stabilize near-term revenue and support LNTH's strategic pivot to PET radiodiagnostics.

17.03.2026

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

BEDFORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has extended its review of the New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide) by three months to June 29, 2026.

Videos

No Data

There is no data to display

Press releases

07.05.2026

Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

17.03.2026

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

06.03.2026

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines the diagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for larger batches and greater patient availability

02.03.2026

Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Lantheus Holdings, Inc. (NasdaqGM: LNTH). In August of 2025, contrary to the Company's prior optimistic outlook for the growth potential of its flagship product, Pylarify, the Company disclosed an 8% year-over-year decline in Pylarify revenue, as well as cuts to its.

Lantheus Holdings, Inc. (LNTH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lantheus Holdings, Inc. (LNTH)

Lantheus Q1 Earnings Call Highlights

These Analysts Raise Their Forecasts On Lantheus After Upbeat Q1 Results

Lantheus Holdings, Inc. (LNTH) Q1 2026 Earnings Call Transcript

Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

Brown Advisory Small Cap Growth Strategy Q1 2026 Portfolio Activity

Lantheus Holdings: Tensions From The PDUFA Extension

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

Videos

No Data

Press releases

Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH

Lantheus Q1 Earnings Call Highlights

These Analysts Raise Their Forecasts On Lantheus After Upbeat Q1 Results

Lantheus Holdings, Inc. (LNTH) Q1 2026 Earnings Call Transcript

Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

Brown Advisory Small Cap Growth Strategy Q1 2026 Portfolio Activity

Lantheus Holdings: Tensions From The PDUFA Extension

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

Videos

No Data

Press releases

Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH

Search stocks

Lantheus Holdings, Inc. (LNTH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lantheus Holdings, Inc. (LNTH)

Lantheus Q1 Earnings Call Highlights

These Analysts Raise Their Forecasts On Lantheus After Upbeat Q1 Results

Lantheus Holdings, Inc. (LNTH) Q1 2026 Earnings Call Transcript

Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

Brown Advisory Small Cap Growth Strategy Q1 2026 Portfolio Activity

Lantheus Holdings: Tensions From The PDUFA Extension

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

Videos

No Data

Press releases

Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH

Lantheus Q1 Earnings Call Highlights

These Analysts Raise Their Forecasts On Lantheus After Upbeat Q1 Results

Lantheus Holdings, Inc. (LNTH) Q1 2026 Earnings Call Transcript

Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

Brown Advisory Small Cap Growth Strategy Q1 2026 Portfolio Activity

Lantheus Holdings: Tensions From The PDUFA Extension

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

Videos

No Data

Press releases

Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH